Multimodality therapy for cerebral vasospasm after SAH

Importance of intensive care and intraarterial injection of fasudil hydrochloride

Shigeki Ono, S. Arimitsu, T. Ogawa, K. Onoda, K. Tokunaga, Kenji Sugiu, Isao Date

Research output: Chapter in Book/Report/Conference proceedingConference contribution

Abstract

Until now, no absolute therapy for cerebral vasospasm (VS) after subarachnoid haemorrhage (SAH) has been established. Here we examine the efficacy of intensive multimodality therapy, contrasting with the treatment in the non-multimodality period in our institute. For 10 years, a total of 108 patients who suffered subarachnoid haemorrhage (SAH) were divided into two groups. Group A patients are from a period of time when there was no particular standardized protocol for treating SAH, i.e. 1996-2000. Group B patients include the intensive care group for treating SAH, and we employed multimodality therapy on Group B by using intraventricular urokinase (UK) injection, lumbar (LD) or cisternal drainages (CD) and timely intraarterial fasudil hydrochloride (FH) injection in the second half of the period with a standardized protocol. Urokinase was given as a bolus administration from a ventricular drain 12 h after surgery, and prophylactic mild hypertension and normovolemia were strictly performed. If symptomatic spasm were detected, immediate intraarterial FH injection or percutaneous transluminal angioplasty was performed. Angiographic and symptomatic vasospasm and the Glasgow outcome scale score 3 months post SAH were evaluated. Angiographic vasospasm occurred in 64.2% and 59% in groups A and B, respectively. Symptomatic vasospasm was observed in 56.5% of Group A and 37.1% of Group B. There was a statistical significance between the percentages of symptomatic vasospasm in Groups A and B (p = 0.0422), but no significant differences were seen in angiographic vasospasm between these 2 groups. As for the outcome, 25.7% of Group A and 10.8% of Group B were poor outcome, and statistical significance (p = 0.001) was seen between these two groups. It is worth noting that there were no deaths due to vasospasm in Group B, in contrast to the 14.8% death rate in Group A. Introduction of multimodality therapy was effective to prevent symptomatic vasospasm and improved the patients' outcome.

Original languageEnglish
Title of host publicationActa Neurochirurgica, Supplementum
Pages279-281
Number of pages3
Edition104
DOIs
Publication statusPublished - 2008

Publication series

NameActa Neurochirurgica, Supplementum
Number104
ISSN (Print)00651419

Fingerprint

Intra-Arterial Injections
Intracranial Vasospasm
Subarachnoid Hemorrhage
Critical Care
Urokinase-Type Plasminogen Activator
Intraventricular Injections
Glasgow Outcome Scale
Therapeutics
Injections
Spasm
Group Psychotherapy
Angioplasty
Drainage
fasudil
Hypertension
Mortality

Keywords

  • Cerebral vasospasm
  • fasudil hydrochloride
  • multimodality therapy
  • urokinase

ASJC Scopus subject areas

  • Clinical Neurology
  • Surgery

Cite this

Ono, S., Arimitsu, S., Ogawa, T., Onoda, K., Tokunaga, K., Sugiu, K., & Date, I. (2008). Multimodality therapy for cerebral vasospasm after SAH: Importance of intensive care and intraarterial injection of fasudil hydrochloride. In Acta Neurochirurgica, Supplementum (104 ed., pp. 279-281). (Acta Neurochirurgica, Supplementum; No. 104). https://doi.org/10.1007/978-3-211-75718-5-57

Multimodality therapy for cerebral vasospasm after SAH : Importance of intensive care and intraarterial injection of fasudil hydrochloride. / Ono, Shigeki; Arimitsu, S.; Ogawa, T.; Onoda, K.; Tokunaga, K.; Sugiu, Kenji; Date, Isao.

Acta Neurochirurgica, Supplementum. 104. ed. 2008. p. 279-281 (Acta Neurochirurgica, Supplementum; No. 104).

Research output: Chapter in Book/Report/Conference proceedingConference contribution

Ono, S, Arimitsu, S, Ogawa, T, Onoda, K, Tokunaga, K, Sugiu, K & Date, I 2008, Multimodality therapy for cerebral vasospasm after SAH: Importance of intensive care and intraarterial injection of fasudil hydrochloride. in Acta Neurochirurgica, Supplementum. 104 edn, Acta Neurochirurgica, Supplementum, no. 104, pp. 279-281. https://doi.org/10.1007/978-3-211-75718-5-57
Ono S, Arimitsu S, Ogawa T, Onoda K, Tokunaga K, Sugiu K et al. Multimodality therapy for cerebral vasospasm after SAH: Importance of intensive care and intraarterial injection of fasudil hydrochloride. In Acta Neurochirurgica, Supplementum. 104 ed. 2008. p. 279-281. (Acta Neurochirurgica, Supplementum; 104). https://doi.org/10.1007/978-3-211-75718-5-57
Ono, Shigeki ; Arimitsu, S. ; Ogawa, T. ; Onoda, K. ; Tokunaga, K. ; Sugiu, Kenji ; Date, Isao. / Multimodality therapy for cerebral vasospasm after SAH : Importance of intensive care and intraarterial injection of fasudil hydrochloride. Acta Neurochirurgica, Supplementum. 104. ed. 2008. pp. 279-281 (Acta Neurochirurgica, Supplementum; 104).
@inproceedings{1298e942b5a84a0d8a7e45f8941cde39,
title = "Multimodality therapy for cerebral vasospasm after SAH: Importance of intensive care and intraarterial injection of fasudil hydrochloride",
abstract = "Until now, no absolute therapy for cerebral vasospasm (VS) after subarachnoid haemorrhage (SAH) has been established. Here we examine the efficacy of intensive multimodality therapy, contrasting with the treatment in the non-multimodality period in our institute. For 10 years, a total of 108 patients who suffered subarachnoid haemorrhage (SAH) were divided into two groups. Group A patients are from a period of time when there was no particular standardized protocol for treating SAH, i.e. 1996-2000. Group B patients include the intensive care group for treating SAH, and we employed multimodality therapy on Group B by using intraventricular urokinase (UK) injection, lumbar (LD) or cisternal drainages (CD) and timely intraarterial fasudil hydrochloride (FH) injection in the second half of the period with a standardized protocol. Urokinase was given as a bolus administration from a ventricular drain 12 h after surgery, and prophylactic mild hypertension and normovolemia were strictly performed. If symptomatic spasm were detected, immediate intraarterial FH injection or percutaneous transluminal angioplasty was performed. Angiographic and symptomatic vasospasm and the Glasgow outcome scale score 3 months post SAH were evaluated. Angiographic vasospasm occurred in 64.2{\%} and 59{\%} in groups A and B, respectively. Symptomatic vasospasm was observed in 56.5{\%} of Group A and 37.1{\%} of Group B. There was a statistical significance between the percentages of symptomatic vasospasm in Groups A and B (p = 0.0422), but no significant differences were seen in angiographic vasospasm between these 2 groups. As for the outcome, 25.7{\%} of Group A and 10.8{\%} of Group B were poor outcome, and statistical significance (p = 0.001) was seen between these two groups. It is worth noting that there were no deaths due to vasospasm in Group B, in contrast to the 14.8{\%} death rate in Group A. Introduction of multimodality therapy was effective to prevent symptomatic vasospasm and improved the patients' outcome.",
keywords = "Cerebral vasospasm, fasudil hydrochloride, multimodality therapy, urokinase",
author = "Shigeki Ono and S. Arimitsu and T. Ogawa and K. Onoda and K. Tokunaga and Kenji Sugiu and Isao Date",
year = "2008",
doi = "10.1007/978-3-211-75718-5-57",
language = "English",
isbn = "9783211757178",
series = "Acta Neurochirurgica, Supplementum",
number = "104",
pages = "279--281",
booktitle = "Acta Neurochirurgica, Supplementum",
edition = "104",

}

TY - GEN

T1 - Multimodality therapy for cerebral vasospasm after SAH

T2 - Importance of intensive care and intraarterial injection of fasudil hydrochloride

AU - Ono, Shigeki

AU - Arimitsu, S.

AU - Ogawa, T.

AU - Onoda, K.

AU - Tokunaga, K.

AU - Sugiu, Kenji

AU - Date, Isao

PY - 2008

Y1 - 2008

N2 - Until now, no absolute therapy for cerebral vasospasm (VS) after subarachnoid haemorrhage (SAH) has been established. Here we examine the efficacy of intensive multimodality therapy, contrasting with the treatment in the non-multimodality period in our institute. For 10 years, a total of 108 patients who suffered subarachnoid haemorrhage (SAH) were divided into two groups. Group A patients are from a period of time when there was no particular standardized protocol for treating SAH, i.e. 1996-2000. Group B patients include the intensive care group for treating SAH, and we employed multimodality therapy on Group B by using intraventricular urokinase (UK) injection, lumbar (LD) or cisternal drainages (CD) and timely intraarterial fasudil hydrochloride (FH) injection in the second half of the period with a standardized protocol. Urokinase was given as a bolus administration from a ventricular drain 12 h after surgery, and prophylactic mild hypertension and normovolemia were strictly performed. If symptomatic spasm were detected, immediate intraarterial FH injection or percutaneous transluminal angioplasty was performed. Angiographic and symptomatic vasospasm and the Glasgow outcome scale score 3 months post SAH were evaluated. Angiographic vasospasm occurred in 64.2% and 59% in groups A and B, respectively. Symptomatic vasospasm was observed in 56.5% of Group A and 37.1% of Group B. There was a statistical significance between the percentages of symptomatic vasospasm in Groups A and B (p = 0.0422), but no significant differences were seen in angiographic vasospasm between these 2 groups. As for the outcome, 25.7% of Group A and 10.8% of Group B were poor outcome, and statistical significance (p = 0.001) was seen between these two groups. It is worth noting that there were no deaths due to vasospasm in Group B, in contrast to the 14.8% death rate in Group A. Introduction of multimodality therapy was effective to prevent symptomatic vasospasm and improved the patients' outcome.

AB - Until now, no absolute therapy for cerebral vasospasm (VS) after subarachnoid haemorrhage (SAH) has been established. Here we examine the efficacy of intensive multimodality therapy, contrasting with the treatment in the non-multimodality period in our institute. For 10 years, a total of 108 patients who suffered subarachnoid haemorrhage (SAH) were divided into two groups. Group A patients are from a period of time when there was no particular standardized protocol for treating SAH, i.e. 1996-2000. Group B patients include the intensive care group for treating SAH, and we employed multimodality therapy on Group B by using intraventricular urokinase (UK) injection, lumbar (LD) or cisternal drainages (CD) and timely intraarterial fasudil hydrochloride (FH) injection in the second half of the period with a standardized protocol. Urokinase was given as a bolus administration from a ventricular drain 12 h after surgery, and prophylactic mild hypertension and normovolemia were strictly performed. If symptomatic spasm were detected, immediate intraarterial FH injection or percutaneous transluminal angioplasty was performed. Angiographic and symptomatic vasospasm and the Glasgow outcome scale score 3 months post SAH were evaluated. Angiographic vasospasm occurred in 64.2% and 59% in groups A and B, respectively. Symptomatic vasospasm was observed in 56.5% of Group A and 37.1% of Group B. There was a statistical significance between the percentages of symptomatic vasospasm in Groups A and B (p = 0.0422), but no significant differences were seen in angiographic vasospasm between these 2 groups. As for the outcome, 25.7% of Group A and 10.8% of Group B were poor outcome, and statistical significance (p = 0.001) was seen between these two groups. It is worth noting that there were no deaths due to vasospasm in Group B, in contrast to the 14.8% death rate in Group A. Introduction of multimodality therapy was effective to prevent symptomatic vasospasm and improved the patients' outcome.

KW - Cerebral vasospasm

KW - fasudil hydrochloride

KW - multimodality therapy

KW - urokinase

UR - http://www.scopus.com/inward/record.url?scp=77957562703&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77957562703&partnerID=8YFLogxK

U2 - 10.1007/978-3-211-75718-5-57

DO - 10.1007/978-3-211-75718-5-57

M3 - Conference contribution

SN - 9783211757178

T3 - Acta Neurochirurgica, Supplementum

SP - 279

EP - 281

BT - Acta Neurochirurgica, Supplementum

ER -